Suven Life Sciences Ltd has secured patents in China and South Africa for its new chemical entities (NCEs) used in CNS therapy through mechanism of action – H3 Inverse agonist and these patents are valid until 2031, 2030 and 2031 respectively. The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.
Besides, Suven received a patent for their NCE in Mexico (326651) and the granted claims of this patent include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD) and the patent is valid through 2030.
With these new patents, Suven has 16, 19 and 22 granted patents from China, Mexico and South Africa respectively.
Besides, Suven received a patent for their NCE in Mexico (326651) and the granted claims of this patent include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD) and the patent is valid through 2030.
With these new patents, Suven has 16, 19 and 22 granted patents from China, Mexico and South Africa respectively.